Predictmedix AI Launches Mobile Platform for AI-Powered Diabetes Screening
A leader in artificial intelligence-driven health screening solutions, is expanding into the direct-to-consumer market with a mobile solution designed to deliver rapid, non-invasive diabetic screening — with India identified as the initial launchpad for this transformative initiative. Leveraging the company’s proprietary AI technology, the platform is intended to empower millions with instant access to diabetic risk assessments using only a smartphone, eliminating the need for blood draws, lab visits, or clinical infrastructure.
Predictmedix AI is expanding into the direct-to-consumer market with a mobile solution designed to deliver rapid, non-invasive diabetic screening.Share
By combining advanced facial and biometric analysis with seamless smartphone delivery, the solution brings accessible, affordable, and scalable diabetic screening to some of the most underserved populations across India. This milestone represents a significant step in Predictmedix AI’s broader vision to reshape global healthcare delivery and accelerate the adoption of AI-enabled, mass-scale preventive health solutions.
“We are addressing a critical gap in healthcare access with a cutting-edge solution that empowers individuals to take control of their health using the device they already own — their mobile phone,” said Dr. Rahul Kushwah, COO of Predictmedix AI. “India has over 100 million diabetics and a significant number remain undiagnosed. Our app is designed to bridge that diagnostic divide.”
Key Features:
- Instant Diabetic Risk Scoring via smartphone.
- AI-driven facial and biometric analysis based on Predictmedix’s proven non-invasive screening platform.
- User-friendly design with multilingual support for broad accessibility.
- Secure, privacy-compliant data handling, in line with India’s Digital Personal Data Protection (DPDP) Act.
Strategic Significance:
India’s diabetes epidemic is accelerating, with estimates projecting nearly 1 in 3 adults to be diabetic or prediabetic by 2045. Simultaneously, smartphone adoption now exceeds 1.1 billion users — a convergence that creates a once-in-a-generation opportunity for mobile-first, AI-powered health solutions.
Our platform is uniquely positioned to:
- Capture significant market share in a high-need, high-growth region.
- Generate recurring revenue streams through direct-to-consumer and B2B channels.
- Align with public health priorities of governments, NGOs, and large employers.
- Scale globally with minimal marginal cost, leveraging cloud-based delivery.
Details of the company’s recent product validations, pilot programs, and strategic partnerships can be found in earlier press releases available at: https://predictmedix.com/press-releases/
About Predictmedix AI Inc.
Predictmedix AI Inc. (CSE: PMED) (OTC: PMEDF) (FRA:3QP) is an emerging provider of rapid health screening and remote patient care solutions globally. The Company’s Safe Entry Stations – powered by a proprietary artificial intelligence (AI) – use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including 19 physiological vital parameters, impairment by drugs or alcohol, fatigue, or various mental illnesses. Predictmedix AI’s proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes. To learn more, please visit our website at www.Predictmedix.com or follow us on Twitter, Instagram or LinkedIn.
